Literature DB >> 11027429

Cell cycle regulators p27 and pRb in lymphomas - correlation with histology and proliferative activity.

M Kiviniemi1, I Sauroja, A Rajamäki, K Punnonen, K O Söderström, E Salminen.   

Abstract

The cell cycle is a complex event in which multiple regulator-proteins participate. The G(1)/S checkpoint of the cell cycle is controlled by pRb protein, which functions in its hypophosphorylated form as a negative regulator of growth. p27 (Kip1), a member of CIP/KIP family of cyclin inhibitory proteins, participates in inhibition of forming complexes that allow pRb to phosphorylate and lead the cell into mitosis. The expression of these important cell cycle regulator proteins was studied in a total of 96 non-Hodgkin's lymphoma (NHL) samples, which were classified according to the REAL classification. The expression of p27, pRb and the cell proliferation marker Ki-67 (MIB-1) was evaluated in lymphomas using immunohistochemistry. This study showed that there were coordinate changes in the expression of p27 and pRb in NHL. When compared to low-grade lymphomas, high-grade lymphomas showed significantly reduced expression of p27 and inversely pRb expression was increased (P< 0.001). Increase in expression of Ki-67 was parallel with pRb expression, and was mainly seen in cells that lacked p27 expression (P< 0.0001). This study suggests that changes in the control of the cell cycle closely relate to the pathobiology of NHL. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027429      PMCID: PMC2363578          DOI: 10.1054/bjoc.2000.1435

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL).

Authors:  Y Hatta; Y Yamada; M Tomonaga; H P Koeffler
Journal:  Leukemia       Date:  1997-07       Impact factor: 11.528

2.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.

Authors:  P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.

Authors:  C Catzavelos; N Bhattacharya; Y C Ung; J A Wilson; L Roncari; C Sandhu; P Shaw; H Yeger; I Morava-Protzner; L Kapusta; E Franssen; K I Pritchard; J M Slingerland
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

Review 4.  Role of the cyclin-dependent kinase inhibitors in the development of cancer.

Authors:  T Hirama; H P Koeffler
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

Review 5.  Inhibitors of mammalian G1 cyclin-dependent kinases.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1995-05-15       Impact factor: 11.361

6.  Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins.

Authors:  M Hall; S Bates; G Peters
Journal:  Oncogene       Date:  1995-10-19       Impact factor: 9.867

7.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Authors:  I Reynisdóttir; K Polyak; A Iavarone; J Massagué
Journal:  Genes Dev       Date:  1995-08-01       Impact factor: 11.361

Review 8.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

9.  Deletions and rearrangement of CDKN2 in lymphoid malignancy.

Authors:  G Stranks; S E Height; P Mitchell; D Jadayel; M A Yuille; C De Lord; R D Clutterbuck; J G Treleaven; R L Powles; E Nacheva
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

10.  Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas.

Authors:  W Yasui; Y Kudo; S Semba; H Yokozaki; E Tahara
Journal:  Jpn J Cancer Res       Date:  1997-07
View more
  3 in total

1.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

Review 2.  Cell kinetics and cell cycle regulation in lymphomas.

Authors:  L Leoncini; S Lazzi; C Bellan; P Tosi
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

3.  pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda.

Authors:  Sam Kalungi; Solrun J Steine; Henry Wabinga; Leif Bostad; Anders Molven
Journal:  BMC Clin Pathol       Date:  2009-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.